What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

J&J's STRONG CANCER PIPELINE

Post by curncman »

As drug developers begin publicizing the cancer treatment advances they’ll present at the June 4 virtual meeting of the American Society of Clinical Oncology, investors may not be watching Johnson & Johnson. They should

J&J has a strong franchise in cancer drugs that is one of the fastest-growing pieces of the healthcare giant. Ten years ago, the company sold about $2 billion worth of cancer drugs a year, J&J’s head of cancer therapies Peter Lebowitz told Barron’s. Sales topped $12 billion last year. In this year’s March quarter, oncology product sales rose 15% (adjusted for currencies), to $3.6 billion.

“There’s been a rapid rise,” said Lebowitz, “and it’s now accelerating, in terms of the drugs that are moving toward approvals.”

J&J’s cancer treatments comprise about 30% of its Janssen drug unit’s sales, and 15% of total J&J revenue, but the category’s strength is an important engine for the diverse seller of drugs, devices, and consumer products. J&J stock is up 18% in the past year to a recent $170, but that’s less than half the gain of the S&P 500 over the same stretch.
curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Which TKI-chemo-HSCT cocktail for Ph+ ALL?

Post by curncman »

Which TKI-chemo-HSCT cocktail for Ph+ ALL?

Yves Chalandon, MD, PhD, University of Geneva, Geneva, Switzerland, discusses the treatment strategies available to treat Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). For adult patients, there have been significant changes with the combination of new generation tyrosine kinase inhibitors (TKIs), like ponatinib, with chemotherapy, or with blinatumomab. However, the follow-up from studies evaluating those combinations is still short. Currently, allogeneic hematopoietic stem cell transplant (allo-HSCT) remains the standard of care for most adult patients with Ph+ ALL, with TKI maintenance after HSCT providing the best results. Prof. Chalandon explains that the GRAAPH 2021 study will help answer whether allo-HSCT is needed or not in the era of third-generation TKI and new immunotherapies. For the pediatric population, the best strategy includes a combination of chemotherapy with second-generation TKIs, such as dasatinib, while allo-HSCT may only be recommended for high-risk patients. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/ref

Post by curncman »

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.

curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Next big wave’: Radiation drugs track and kill cancer cells

Post by curncman »

Next big wave’: Radiation drugs track and kill cancer cells
https://apnews.com/article/cancer-scien ... ba505d2e54

https://apnews.com/article/cancer-scien ... 5184211b84

Doctors are reporting improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumor cells.

Few such drugs are approved now, but the approach may become a new way to treat patients with other hard-to-reach or inoperable cancers.

The study tested an emerging class of medicine called radiopharmaceuticals, drugs that deliver radiation directly to cancer cells. The drug in this case is a molecule that contains two parts: a tracker and a cancer-killing payload.

Trillions of these molecules hunt down cancer cells, latching onto protein receptors on the cell membrane. The payload emits radiation, which hits the tumor cells within its range.

“You can treat tumors that you cannot see. Anywhere the drug can go, the drug can reach tumor cells,” said Dr. Frank Lin, who had no role in the study but heads a division at the National Cancer Institute that helps develop such medicine.
curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Allogeneic Cell Therapies Summit May 2021 | Dr. Ezequiel Zylberberg

Post by curncman »

Allogeneic Cell Therapies Summit May 2021 | Dr. Ezequiel Zylberberg






curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Meet The PhDs - Episode 11 - Part 1 - Guest - Kannan Thangamani - UTSA - The USA - Direct PhD

Post by curncman »

Meet The PhDs - Episode 11 - Part 1 - Guest - Kannan Thangamani - UTSA - The USA - Direct PhD


curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

2nd International Webinar on Cancer research & Therapy 2021 presentation by Pravin D. Potdar

Post by curncman »

2nd International Webinar on Cancer research & Therapy 2021 presentation by Pravin D. Potdar

curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Off-the-shelf iPSC therapies for solid tumors

Post by curncman »

Off-the-shelf iPSC therapies for solid tumors
Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, discusses the benefits of utilizing allogenic stem cell platforms over autologous approaches that involve the need for patients to undergo leukapheresis and a time-consuming cell manufacturing process, which is an issue in patients with late-stage cancer. Off-the-shelf allogeneic induced pluripotent stem cell (iPSC) platforms offer the potential for consistent, genetically engineered therapies that can be offered to patients more quickly. Adaptimmune’s allogeneic platform is being leveraged to develop off-the-shelf products that function in the same manner as their existing autologous products already being evaluated in clinical trials for solid tumors. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.




curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Biologics and the Supply Chain Ballet

Post by curncman »

Biologics and the Supply Chain Ballet

curncman
Posts: 1158
Joined: Fri Jun 26, 2020 8:27 am

Challenges of NK cell therapy in solid tumors

Post by curncman »



Connect to Science “Innovation Insights” series: Grow enough NK cells for cell therapy development



Post Reply